Npx372

Phase 1

NNextPoint Therapeutics, Inc.

Npx372 is one of 11 therapeutic programs targeting Metastatic Malignant Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Malignant NeoplasmRecruiting

Metastatic Malignant NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Metastatic Malignant Neoplasm

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—2

Celebrex

PPhiladelphia Eye Associates

Approved

—3

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Taxotere

Mitosol

Keytruda

1 7

Ibrance

Pfizer

Phase 2

1 8

Tylenol

Oxycontin

Npx372

NNextPoint Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Metastatic Malignant Neoplasm

NCT07563829

Clinical

Trials by Indication[1]

Metastatic Malignant Neoplasm1 trial

A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies

Recruiting·NNextPoint Therapeutics, Inc.·Phase 1·NCT07563829·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Npx372. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Npx372. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — NextPoint Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNextPoint Therapeutics, Inc.

Npx372

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Metastatic Malignant Neoplasm1 trial

References

Drug Info

Quick Facts

Related News